Zogenix, Inc. (NASDAQ:ZGNX) Director Renee P. Tannenbaum bought 5,000 shares of the stock in a transaction on Thursday, March 16th. The stock was purchased at an average price of $11.00 per share, with a total value of $55,000.00. Following the completion of the purchase, the director now owns 10,000 shares of the company’s stock, valued at $110,000. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Zogenix, Inc. (NASDAQ:ZGNX) opened at 10.70 on Monday. The stock’s market cap is $265.50 million. The firm has a 50 day moving average of $10.05 and a 200-day moving average of $10.43. Zogenix, Inc. has a 12-month low of $7.33 and a 12-month high of $13.70.
TRADEMARK VIOLATION WARNING: “Zogenix, Inc. (ZGNX) Director Purchases $55,000.00 in Stock” was first reported by BBNS and is the property of of BBNS. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://baseballnewssource.com/markets/renee-p-tannenbaum-purchases-5000-shares-of-zogenix-inc-zgnx-stock-updated/518020.html.
Several brokerages have weighed in on ZGNX. Aegis began coverage on shares of Zogenix in a research note on Tuesday, February 14th. They issued a “buy” rating and a $28.00 target price for the company. Zacks Investment Research downgraded shares of Zogenix from a “buy” rating to a “hold” rating in a research note on Wednesday, March 15th.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. A.R.T. Advisors LLC bought a new position in shares of Zogenix during the fourth quarter valued at about $154,000. Oppenheimer & Co. Inc. bought a new position in shares of Zogenix during the third quarter valued at about $169,000. Bailard Inc. bought a new position in shares of Zogenix during the third quarter valued at about $1,388,000. City Financial Investment Co Ltd bought a new position in shares of Zogenix during the fourth quarter valued at about $1,393,000. Finally, Senzar Asset Management LLC bought a new position in shares of Zogenix during the fourth quarter valued at about $1,921,000. Institutional investors and hedge funds own 84.32% of the company’s stock.
Zogenix Company Profile
Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders in requirement of treatment alternatives. The Company’s areas of focus are epilepsy and schizophrenia.
Receive News & Ratings for Zogenix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix Inc. and related companies with our FREE daily email newsletter.